The Role of Th17-Related Cytokines in Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.
Abstract
T helper-17 (Th17) cells, which mainly produce IL-17, are associated with development of various autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis, and psoriasis. IL-17 and related cytokines are therapeutic targets of these diseases. In atopic dermatitis (AD), Th2 cytokines such as IL-4 and IL-13 are regarded to be the main player of the disease; however, Th17 cytokines are also expressed in AD skin lesions. Expression of IL-22 rather than IL-17 is predominant in AD skin, which is contrary to cytokine expression in psoriasis skin. Relatively low IL-17 expression in AD skin can induce relatively low antimicrobial peptide expression, which may be a reason why bacterial infection is frequently seen in AD patients. Failure of clinical trials for investigating the efficacy of anti-IL-12/23 p40 in AD has suggested that IL-17 expressed in skin lesions should not be the main player but a bystander responding to barrier dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Proliferation of epidermal cells, AMP expression, vascular formation, and infiltration of Th17, neutrophils, and macrophages, commonly seen in wounded skin and in psoriasis skin. We sometimes experience fungal infection in patients treated with anit-IL7A or anti-IL17 receptor A antibody. Considering that Th17 cytokines are expressed in various skin diseases with barrier dysfunction and that antibodies against IL-12/IL-23p40 or IL-17A are not effective for AD, IL-17 and its related cytokine expression can be regarded as a common defense mechanism in the skin. Relatively low AMP expression leads to a higher risk of infection seen in AD and CTCL [77,78]. Targeting the Th17 cytokine has been successful for psoriasis, but may not be always the case in other skin diseases.](https://figures.cochat.ai/paper-figures/ed84282be6714f7887f1a44756b5fdc2/the-role-of-th17-related-cytokines-in-atopic-dermatitis-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upregulation of these receptors by PAHs can lead to disruption of the skin barrier and skewing of the immune response towards a Th2 phenotype, which is central to the development and progression of AD [23–25].”
From The Burden of Air Pollution on Skin Health: a Brief Report and Call to Action (2024) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873 · cited 1×
“Th17 cells, which are different from Th1 or Th2 cells, produce IL-17, IL-17F, and IL-22 as well as IL-21 [21].”
BackgroundDefensins: antimicrobial peptides of innate immunity
Ganz, T. (2003) · Nature Reviews Immunology · doi:10.1038/nri1180 · Cited by 3,066 · cited 1×
“IL-17 also increases production of antimicrobial peptides (AMPs), which are part of the innate immune response and are found among all classes of life [30,31].”
BackgroundHuman epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183 · cited 4×
“The intrinsic type is characterized by the lower expression of IL-4, IL-5, and IL-13, and the higher expression of IFN-γ.”
BackgroundInfluentialLeonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261 · cited 2×
“Cytokines Clinical Response References IL-17A Worsening of dermatitis [57–59] IL-12/23p40 No effect in clinical trial [55,56] IL-22 Effective for some patients [60,61] IL-4/13 Very effective [68]”
BackgroundSonnenberg, G. F., Fouser, L. A., & Artis, D. (2011) · Nature Immunology · doi:10.1038/ni.2025 · Cited by 1,044 · cited 2×
“IL-22, which is another cytokine expressed by Th17, enhances AMP production together with IL-17 [31].”
BackgroundA role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis
Salimi, M., Barlow, J. L., Saunders, S. P., Xue, L., Gutowska-Owsiak, D., Wang, X., Huang, L.-C., Johnson, D., Scanlon, S. T., McKenzie, A. N. J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130351 · Cited by 979
Jovanović, D., Battista, J. A. D., Pelletier, J., Jolicoeur, F. C., He, Y., Zhang, M., Mineau, F., & Martel‐Pelletier, J. (1998) · PubMed · Cited by 973
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Jovanovic, D. V., Di Battista, J. A., Martel-Pelletier, J., Jolicoeur, F. C., He, Y., Zhang, M., Mineau, F., & Pelletier, J.-P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3513 · Cited by 867
Boniface, K., Bernard, F.-X., Garcia, M., Gurney, A. L., Lecron, J.-C., & Morel, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3695 · Cited by 864 · cited 1×
“This cytokine induces epidermal proliferation [33].”
Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis
Koga, C., Kabashima, K., Shiraishi, N., Kobayashi, M., & Tokura, Y. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.111 · Cited by 671 · cited 1×
“The percentage of IL-17-poducing CD4+ T cells in peripheral blood from AD patients was increased and associated with severity of AD [16].”
BackgroundKim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30379-6 · Cited by 669
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657 · cited 1×
“A principal component analysis using real-time PCR data clustered the Asian AD phenotype between the European American AD and psoriasis phenotypes [19].”
MethodNograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627 · cited 1×
“When examining skin samples from AD, psoriasis, and healthy controls, IL-17 expression level was increased in AD skin compared to normal skin, although it was much lower than that in psoriasis skin [18].”
BackgroundPrince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31266-7 · Cited by 588 · cited 1×
“This kind of strategy targeting surface molecules should be adopted for the treatment of malignancy [79,80].”
BackgroundKakinuma, T., Nakamura, K., Wakugawa, M., Mitsui, H., Tada, Y., Saeki, H., Torii, H., Asahina, A., Onai, N., Matsushima, K., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.113237 · Cited by 575 · cited 1×
“Serum TARC levels are useful as a marker of the disease activity of AD, which are more sensitive than serum IgE levels, lactate dehydrogenaselevels, and peripheral blood eosinophil counts [63].”
BackgroundSuárez-Fariñas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., de Guzman Strong, C., Krueger, J. G., & Guttman-Yassky, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.046 · Cited by 483 · cited 2×
“In patients with intrinsic AD, Th17-related cytokines are highly expressed [39].”
BackgroundKhader, S. A., Gaffen, S. L., & Kolls, J. K. (2009) · Mucosal Immunology · doi:10.1038/mi.2009.100 · Cited by 481 · cited 1×
“Injury of the mucosa causes fast expansion of Th17 cells and their induction [75].”
BackgroundImai, Y., Yasuda, K., Sakaguchi, Y., Haneda, T., Mizutani, H., Yoshimoto, T., Nakanishi, K., & Yamanishi, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307321110 · Cited by 431
Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Esaki, H., Brunner, P. M., Renert-Yuval, Y., Czarnowicki, T., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., Johnson, D. B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.013 · Cited by 428
Keratin 6, 16 and 17—Critical Barrier Alarmin Molecules in Skin Wounds and Psoriasis
Zhang, X., Yin, M., & Zhang, L.-J. (2019) · Cells · doi:10.3390/cells8080807 · Cited by 417 · cited 1×
“Expression of K6 and K16 is increased and that of K1 and K10 is decreased [69,70].”
BackgroundLesional expression of interferon-γ in atopic eczema
Grewe, M., Gyufko, K., Schöpf, E., & Krutmann, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90879-6 · Cited by 406
Periostin promotes chronic allergic inflammation in response to Th2 cytokines
Masuoka, M., Shiraishi, H., Ohta, S., Suzuki, S., Arima, K., Aoki, S., Toda, S., Inagaki, N., Kurihara, Y., Hayashida, S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58978 · Cited by 388 · cited 2×
“Th2 cytokines IL-4 and IL-13 stimulated fibroblasts to produce periostin, which interacted with a functional periostin receptor on keratinocytes [65].”
BackgroundMicrobial Symbiosis with the Innate Immune Defense System of the Skin
Gallo, R. L., & Nakatsuji, T. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.182 · Cited by 387 · cited 1×
“Skin-resident commensal microbes produce their own AMPs, act to enhance the normal production of AMPs by keratinocytes, and are beneficial to maintaining inflammatory homeostasis by suppressing excess cytokine release after minor epidermal injury [32].”
BackgroundKabashima, K. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.02.001 · Cited by 361 · cited 1×
“The pathogenesis of AD can be explained from the perspectives of the skin barrier, allergic inflammation, and neuroendocrine dysfunction represented by severe pruritus [10].”
BackgroundExtrinsic and intrinsic types of atopic dermatitis
Tokura, Y. (2010) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2010.02.008 · Cited by 349 · cited 10×
“It was recently reported that the frequency of IL-13+ cells, which was correlated with IgE levels and SCORing AD (SCORAD) score, was associated with IL-22-producing T cells in severe AD patients [36].”
BackgroundInfluentialGuttman-Yassky, E., Brunner, P. M., Neumann, A. U., Khattri, S., Pavel, A. B., Malik, K., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.016 · Cited by 343 · cited 2×
“Cytokines Clinical Response References IL-17A Worsening of dermatitis [57–59] IL-12/23p40 No effect in clinical trial [55,56] IL-22 Effective for some patients [60,61] IL-4/13 Very effective [68]”
BackgroundMethodA Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Gordon, K. B., Duffin, K. C., Bissonnette, R., Prinz, J. C., Wasfi, Y., Li, S., Shen, Y.-K., Szapary, P., Randazzo, B., & Reich, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501646 · Cited by 306 · cited 6×
“Monoclonal antibodies against TNF-α, IL-12/23p40 subunit, IL-23p19, and IL-17 are clinically used and very effective [22–25].”
BackgroundInfluentialJones, C. E., & Chan, K. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.26.6.4757 · Cited by 289
Roussel, L., Houle, F., Chan, C., Yao, Y., Bérubé, J., Olivenstein, R., Martin, J. G., Huot, J., Hamid, Q., Ferri, L., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903162 · Cited by 272 · cited 1×
“It also stimulates blood endothelial cells to produce chemoattractants and express VCAM-1 and ICAM-1 in a p38 MAPK-dependent manner, which helps immune cells evade from blood to tissues [28].”
BackgroundSparber, F., De Gregorio, C., Steckholzer, S., Ferreira, F. M., Dolowschiak, T., Ruchti, F., Kirchner, F. R., Mertens, S., Prinz, I., Joller, N., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.02.002 · Cited by 255 · cited 1×
“A murine epicutaneous infection model showed that Malassezia, which has been reported to exacerbate AD skin conditions, selectively induced IL-17-related cytokines [43].”
BackgroundEyerich, K., Pennino, D., Scarponi, C., Foerster, S., Nasorri, F., Behrendt, H., Ring, J., Traidl-Hoffmann, C., Albanesi, C., & Cavani, A. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.10.031 · Cited by 246 · cited 1×
“There was another study showing that more IL-17-producing cells infiltrated into the site of an atopy patch test than in healthy skin [17].”
ResultGrowth Factor FGF2 Cooperates with Interleukin-17 to Repair Intestinal Epithelial Damage
Song, X., Dai, D., He, X., Zhu, S., Yao, Y., Gao, H., Wang, J., Qu, F., Qiu, J., Wang, H., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.024 · Cited by 243 · cited 1×
“FGF2 or IL-17 deficiency resulted in impaired epithelial proliferation, increased pro-inflammatory microbiota outgrowth, and consequently worse pathology in a mouse colitis model [74].”
BackgroundAllergic vs nonallergic asthma: what makes the difference?
Romanet‐Manent, S., Charpin, D., Magnan, A., Lanteaume, A., Vervloet, D., & and the EGEA Cooperative Group (2002) · Allergy · doi:10.1034/j.1398-9995.2002.23504.x · Cited by 235 · cited 2×
“IL-26, another Th17 cytokine, promoted production of various cytokines such as IL-8, IL-1β, CCL20, IL-33, and β-defensin 2 by keratinocytes through phosphorylation of signal transducer and activator of transcription 1 and signal transducer and activator of transcription 3 [37].”
BackgroundCzarnowicki, T., Gonzalez, J., Shemer, A., Malajian, D., Xu, H., Zheng, X., Khattri, S., Gilleaudeau, P., Sullivan-Whalen, M., Suárez-Fariñas, M., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.020 · Cited by 221 · cited 1×
“It was recently reported that the frequency of IL-13+ cells, which was correlated with IgE levels and SCORing AD (SCORAD) score, was associated with IL-22-producing T cells in severe AD patients [36].”
BackgroundEfficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis
Khattri, S., Brunner, P. M., Garcet, S., Finney, R., Cohen, S. R., Oliva, M., Dutt, R., Fuentes‐Duculan, J., Zheng, X., Li, X., et al. (2017) · Experimental Dermatology · doi:10.1111/exd.13112 · Cited by 214 · cited 3×
“Cytokines Clinical Response References IL-17A Worsening of dermatitis [57–59] IL-12/23p40 No effect in clinical trial [55,56] IL-22 Effective for some patients [60,61] IL-4/13 Very effective [68]”
BackgroundNakashima, T., Jinnin, M., Yamane, K., Honda, N., Kajihara, I., Makino, T., Masuguchi, S., Fukushima, S., Okamoto, Y., Hasegawa, M., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100591 · Cited by 210 · cited 1×
“IL-17A expression was significantly increased in the involved skin and sera of systemic sclerosis patients, suggesting possible roles in the development of the disease [47,48].”
Brunner, P. M., Pavel, A. B., Khattri, S., Leonard, A., Malik, K., Rose, S., Jim On, S., Vekaria, A. S., Traidl-Hoffmann, C., Singer, G. K., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.028 · Cited by 201 · cited 2×
“Cytokines Clinical Response References IL-17A Worsening of dermatitis [57–59] IL-12/23p40 No effect in clinical trial [55,56] IL-22 Effective for some patients [60,61] IL-4/13 Very effective [68]”
BackgroundThe natural history of childhood eczema: observations from the British 1958 birth cohort study
Williams, & Strachan (1998) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1998.02509.x · Cited by 189 · cited 2×
“Remission can be achieved by conventional treatment for mild or moderate AD, while it is very difficult for severe AD patients [3,4].”
BackgroundClinical Practice Guidelines for the Management of Atopic Dermatitis 2016
Saeki, H., Nakahara, T., Tanaka, A., Kabashima, K., Sugaya, M., Murota, H., Ebihara, T., Kataoka, Y., Aihara, M., Etoh, T., et al. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13392 · Cited by 172
Self-citationIL-17A as an Inducer for Th2 Immune Responses in Murine Atopic Dermatitis Models
Nakajima, S., Kitoh, A., Egawa, G., Natsuaki, Y., Nakamizo, S., Moniaga, C. S., Otsuka, A., Honda, T., Hanakawa, S., Amano, W., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.51 · Cited by 169
Interleukin-17A Promotes IgE Production in Human B Cells
Milovanović, M., Drozdenko, G., Weise, C., Babina, M., & Worm, M. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.175 · Cited by 145 · cited 1×
“It is also known that IL-17 promotes the differentiation of B cells to IgE-producing plasma cells [42].”
BackgroundBrockmann, L., Giannou, A., Gagliani, N., & Huber, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051033 · Cited by 144 · cited 2×
“Th17 cells produce various cytokines, such as TNF-α, IL-17, and IL-22, which can promote cell survival and proliferation, and thus tissue regeneration, in several organs including the skin [72].”
BackgroundCathepsin D is involved in the regulation of transglutaminase 1 and epidermal differentiation
Egberts, F., Heinrich, M., Jensen, J.-M., Winoto-Morbach, S., Pfeiffer, S., Wickel, M., Schunck, M., Steude, J., Saftig, P., Proksch, E., et al. (2004) · Journal of Cell Science · doi:10.1242/jcs.01075 · Cited by 129 · cited 1×
“Increased expression of cathepsin D, which modulates expression of involucrin, loricrin, and filaggrin, has been reported [71].”
BackgroundPathogenesis of Atopic Dermatitis: Current Paradigm.
Furue, M., Ulzii, D., Vu, Y. H., Tsuji, G., Kido‐Nakahara, M., & Nakahara, T. (2019) · PubMed · doi:10.22034/iji.2019.80253 · Cited by 123 · cited 5×
“Abbreviations AD atopic dermatitis CTCL cutaneous T-cell lymphoma TNF tumor necrosis factor Th T helper IL interleukin IFN interferon AMPs antimicrobial peptides TARC thymus and activation-regulated chemokine SCORAD SCORing AD TWEAK TNF-like weak inducer of apoptosis FGF fibroblast growth factor MF mycosis fungoides S…”
BackgroundInfluential[CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF ATOPIC DERMATITIS 2018].
Ebihara, T. (2021) · PubMed · doi:10.15036/arerugi.70.1186 · Cited by 119
Saeki, H., Kabashima, K., Tokura, Y., Murata, Y., Shiraishi, A., Tamamura, R., Randazzo, B., & Imanaka, K. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15493 · Cited by 118 · cited 3×
“Cytokines Clinical Response References IL-17A Worsening of dermatitis [57–59] IL-12/23p40 No effect in clinical trial [55,56] IL-22 Effective for some patients [60,61] IL-4/13 Very effective [68]”
BackgroundMethodEvolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood
Czarnowicki, T., He, H., Canter, T., Han, J., Lefferdink, R., Erickson, T., Rangel, S., Kameyama, N., Kim, H. J., Pavel, A. B., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.09.031 · Cited by 118 · cited 1×
“It was also reported that Th1 cytokines like interferon (IFN)-γ were expressed in AD lesional skin [14,15].”
IL-22, but Not IL-17, Dominant Environment in Cutaneous T-cell Lymphoma
Miyagaki, T., Sugaya, M., Suga, H., Kamata, M., Ohmatsu, H., Fujita, H., Asano, Y., Tada, Y., Kadono, T., & Sato, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1192 · Cited by 116 · cited 1×
“Our group reported that lesional skin of mycosis fungoides (MF) and Sezary syndrome (SS), representative diseases of CTCL, contained a high amount of IL-17 and IL-22, the latter of which was dominant [49].”
BackgroundSelf-citationIL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells
Chen, X., Cai, G., Liu, C., Zhao, J., Gu, C., Wu, L., Hamilton, T. A., Zhang, C.-J., Ko, J., Zhu, L., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20171849 · Cited by 106 · cited 1×
“The cytokine mediates activation of EGFR, which is critical for the expansion and migration of Lrig1+ stem cells, promoting wound healing [73].”
BackgroundNormal psoriatic epidermis expression of hyperproliferation-associated keratins
Thewes, M., Stadler, R., Korge, B. P., & Mischke, D. (1991) · Archives of Dermatological Research · doi:10.1007/bf00371784 · Cited by 101 · cited 1×
“Expression of K6 and K16 is increased and that of K1 and K10 is decreased [69,70].”
BackgroundTakahashi, N., Sugaya, M., Suga, H., Oka, T., Kawaguchi, M., Miyagaki, T., Fujita, H., & Sato, S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0992 · Cited by 99 · cited 1×
“It was recently reported that the TSLP receptor was expressed by some T cell subsets from patients with Th2-dominant diseases and that TSLP directly enhanced IL-4/IL-13 production by T cells [66,67].”
BackgroundSelf-citationTatsuno, K., Fujiyama, T., Yamaguchi, H., Waki, M., & TOKURA, Y. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.318 · Cited by 97 · cited 1×
“It was recently reported that the TSLP receptor was expressed by some T cell subsets from patients with Th2-dominant diseases and that TSLP directly enhanced IL-4/IL-13 production by T cells [66,67].”
BackgroundXu, X., van Galen, L. S., Koh, M. J. A., Bajpai, R. C., Thng, S. T. G., Yew, Y. W., Ho, V. P. Y., Alagappan, U., Järbrink, K., & Car, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-51129-5 · Cited by 95 · cited 1×
“AD has significant negative social and economic impacts, substantially decreasing the quality of life of the patients and their families [8,9].”
BackgroundSkin Barrier Dysfunction and Low Antimicrobial Peptide Expression in Cutaneous T-cell Lymphoma
Suga, H., Sugaya, M., Miyagaki, T., Ohmatsu, H., Kawaguchi, M., Takahashi, N., Fujita, H., Asano, Y., Tada, Y., Kadono, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0077 · Cited by 68 · cited 5×
“Other skin diseases such as cutaneous T-cell lymphoma (CTCL), drug eruption, and bullous diseases should be considered as a possible diagnosis.”
BackgroundSelf-citationThe use of biologics for immune modulation in allergic disease
van de Veen, W., & Akdiş, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124607 · Cited by 67
IL-26 contributes to host defense against intracellular bacteria
Dang, A. T., Teles, R. M. B., Weiss, D. I., Parvatiyar, K., Sarno, E. N., Ochoa, M. T., Cheng, G., Gilliet, M. F., Bloom, B. R., & Modlin, R. L. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99550 · Cited by 67 · cited 1×
“IL-26, an antimicrobial protein that has the ability to directly kill extracellular bacteria, is also secreted by Th17 [34].”
BackgroundHayashida, S., Uchi, H., Moroi, Y., & Furue, M. (2010) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2010.10.013 · Cited by 65 · cited 2×
“Another group, however, showed that the number of Th1 and Th17 subsets in peripheral blood from AD patients was significantly decreased, but that of the Th2 subset was similar to that of normal controls [35].”
BackgroundResultMiyagaki, T., & Sugaya, M. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.07.007 · Cited by 62
Self-citationIL-17 Promotes Scar Formation by Inducing Macrophage Infiltration
Zhang, J., Qiao, Q., Liu, M., He, T., Shi, J., Bai, X., Zhang, Y., Li, Y., Cai, W., Han, S., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.04.005 · Cited by 62 · cited 1×
“IL-17 promoted macrophage infiltration into wounded skin and scar formation through an indirect mechanism [76].”
BackgroundKamijo, H., Miyagaki, T., Hayashi, Y., Akatsuka, T., Otobe, S., Oka, T., Shishido-Takahashi, N., Suga, H., Sugaya, M., & Sato, S. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.07.713 · Cited by 56
Self-citationPsoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine
Zackheim, H. S., Koo, J. Y. M., LeBoit, P. E., McCalmont, T. H., Bowman, P. H., Kashani–Sabet, M., Jones, C. D., & Zehnder, J. L. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120571 · Cited by 55
Inadequate response to ustekinumab in atopic dermatitis – a report of two patients
Samorano, L. P., Hanifin, J. M., Simpson, E. L., & Leshem, Y. A. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12918 · Cited by 55
Miyagaki, T., & Sugaya, M. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.02.010 · Cited by 46 · cited 5×
“Other skin diseases such as cutaneous T-cell lymphoma (CTCL), drug eruption, and bullous diseases should be considered as a possible diagnosis.”
BackgroundSelf-citationAtopic-like dermatitis after secukinumab injection: A case report
Burlando, M., Cozzani, E., Russo, R. L., & Parodi, A. (2018) · Dermatologic Therapy · doi:10.1111/dth.12751 · Cited by 46 · cited 1×
“Another group reported a 70-year-old woman with intractable psoriasis vulgaris treated with 300 mg of secukinumab [58].”
BackgroundInterleukin-17 pathways in systemic sclerosis-associated fibrosis
Ahmed, S., Misra, D. P., & Agarwal, V. (2019) · Rheumatology International · doi:10.1007/s00296-019-04317-5 · Cited by 46 · cited 1×
“IL-17A expression was significantly increased in the involved skin and sera of systemic sclerosis patients, suggesting possible roles in the development of the disease [47,48].”
BackgroundFernández-Antón Martínez, M. C., Alfageme Roldán, F., Ciudad Blanco, C., & Suárez Fernández, R. (2014) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2013.05.003 · Cited by 44
Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab
Agusti-Mejias, A., Messeguer, F., García, R., & Febrer, I. (2013) · Annals of Dermatology · doi:10.5021/ad.2013.25.3.368 · Cited by 44 · cited 1×
“A 16-year-old woman with over a 13-year history of severe AD was also reported to show clearance of severe itch after one injection of ustekinumab 45 mg, although it had been resistant to phototherapy and systemic agents such as cyclosporine and azathioprine [51].”
BackgroundSaeki, H., Oiso, N., Honma, M., Iizuka, H., Kawada, A., & Tamaki, K. (2009) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2009.04.004 · Cited by 41 · cited 1×
“In Japan, AD is not a rare skin disease, whose frequency is about 10–15% until the age of forty [2].”
BackgroundFernández-Antón Martínez, M. C., Alfageme Roldán, F., Ciudad Blanco, C., & Suárez Fernández, R. (2014) · Actas Dermo-Sifiliográficas (English Edition) · doi:10.1016/j.adengl.2013.05.005 · Cited by 39 · cited 1×
“A previous report about four male patients with severe AD between 23 and 29 years old, whose skin eruption had been refractory to oral corticosteroids, phototherapy, and to at least two systemic drugs, showed improvement of SCORAD and itch score after treatment with 45 mg of ustekinumab injection at 0, 4 weeks, and ev…”
BackgroundIshiuji, Y., Umezawa, Y., Asahina, A., Fukuta, H., Aizawa, N., Yanaba, K., & Nakagawa, H. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14295 · Cited by 34 · cited 1×
“Another group reported two psoriatic patients with high serum IgE levels, in whom ustekinumab completely improved psoriasis but paradoxically provoked or exacerbated AD-like symptoms [54].”
BackgroundParadoxical eczematous reaction to ixekizumab
Munera‐Campos, M., Ballescá, F., Richarz, N. A., Ferrándiz, C., & Carrascosa, J. M. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15156 · Cited by 29 · cited 1×
“A 31-year-old man with severe psoriasis treated with ixekizumab presented with a one-month history of pruritic lesions [57].”
BackgroundKim, M. H., Jin, S., Jang, S., Choi, J., Chung, D. H., Lee, D. H., Kim, K. H., & Kim, H. Y. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.08.447 · Cited by 29
Lis‐Święty, A., Skrzypek‐Salamon, A., Arasiewicz, H., & Brzezińska-Wcisło, L. A. (2015) · Allergology International · doi:10.1016/j.alit.2015.06.003 · Cited by 28 · cited 1×
“A 21-year-old man with a 7-year history of severe psoriasis refractory to conventional systemic treatments and childhood AD history was treated with ustekinumab [52].”
BackgroundShibata, M., Shintaku, Y., Matsuzaki, K., & Uematsu, S. (2014) · Orthodontics and Craniofacial Research · doi:10.1111/ocr.12033 · Cited by 22 · cited 1×
“It activates macrophages to express TNF-α and IL-1β [26] and fibroblasts to produce IL-6, IL-8, and matrix metalloproteinases [27].”
BackgroundDoes age influence the quality of life in children with atopic dermatitis?
Đurović, M. R., Janković, J., Tomić-Spirić, V., Relic, M., Timotijević, Z. S., Cirkovic, A. M., Đurić, S., & Janković, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224618 · Cited by 22
A Case of Mycosis Fungoides with Large Cell Transformation Associated with Infliximab Treatment
Suga, H., Sugaya, M., Toyama, T., Sumida, H., Fujita, H., Kogure, A., Igarashi, A., & Sato, S. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-1675 · Cited by 21
Self-citationFukiwake, N., Furusyo, N., Kubo, N., Takeoka, H., Toyoda, K., Morita, K., Shibata, S., Nakahara, T., Makiko, K. I. D. O., Hayashida, S., et al. (2006) · PubMed · Cited by 20
Experimental atopic dermatitis is dependent on the TWEAK/Fn14 signaling pathway
Liu, Q., Wang, H., Wang, X., Lü, M., Tan, X., Peng, L., Tan, F., Xiao, T., Xiao, S., & Xia, Y. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13373 · Cited by 18 · cited 1×
“BALB/c mice deficient in this molecule showed attenuated skin inflammation in an AD model, accompanied by less infiltration of inflammatory cells and lower local levels of proinflammatory cytokines, including TWEAK, TNF-α, and IL-17 [44].”
BackgroundShen, H., Fan, Y., Wang, Y., Zhao, C., Zhang, Z., Pan, H., & Wu, G. (2019) · Immunological Investigations · doi:10.1080/08820139.2019.1699107 · Cited by 18 · cited 1×
“For example, IL-17 expression is reported to be increased in sera or lesional skin of systemic lupus erythematosus [46].”
BackgroundEczematous reaction to ixekizumab successfully treated with dupilumab
Napolitano, M., Gallo, L., Patruno, C., Fabbrocini, G., & Megna, M. (2020) · Dermatologic Therapy · doi:10.1111/dth.13218 · Cited by 13
Research works printed but not linked: 1
- Furue, 2019, Pathogenesis of atopic dermatitis: CurrentpParadigm, Iran. J. Immunol., 16, 97
Cited by
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I.-H., Chung, W.-H., Wu, P.-C., & Chen, C.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 329
“These cytokines promote cell proliferation and macrophage infiltration into damaged skin and stimulate eosinophils to secrete profibrotic cytokines (29).”
BackgroundSkin Barrier Function: The Interplay of Physical, Chemical, and Immunologic Properties
Baker, P., Huang, C., Radi, R., Moll, S. B., Jules, E., & Arbiser, J. L. (2023) · Cells · doi:10.3390/cells12232745 · Cited by 192
“IL-17 is expressed in atopic dermatitis lesions in relatively low concentrations [96].”
BackgroundExploring the Role of Staphylococcus aureus in Inflammatory Diseases
Chen, H., Zhang, J., He, Y., Lv, Z., Liang, Z., Chen, J., Li, P., Liu, J., Yang, H., Tao, A., et al. (2022) · Toxins · doi:10.3390/toxins14070464 · Cited by 179
Meng, J., Li, Y., Fischer, M. J. M., Steinhoff, M. S., Chen, W., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696784 · Cited by 117
Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis
Kader, H. A., Azeem, M., Jwayed, S. A., Al-Shehhi, A., Tabassum, A., Ayoub, M. A., Hetta, H. F., Waheed, Y., Iratni, R., Aldhaheri, A., et al. (2021) · Cells · doi:10.3390/cells10061392 · Cited by 105
Metadata
- Authors
- Sugaya, M.
- Affiliations
- International University of Health and Welfare Ichikawa Medical Center (JP)
- Corresponding author
- Sugaya, Makoto
- ORCID
- Sugaya, Makoto
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-02-15
- Volume
- 21
- Issue
- 4
- Pages
- 1314
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7072946
- OpenAlex
- W3006169882
- Semantic Scholar
- 1393156b84cfca45fd4122ed4220e8af97991f3b
- Cited by
- 204
- References
- 84
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 48 · 2023: 32 · 2022: 42 · 2021: 23 · 2020: 12
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Keywords
- atopic dermatitis, Th17 cells, IL-17, IL-22, Th2 cytokines, IL-4, IL-13, antimicrobial peptides, bacterial skin infections, skin barrier dysfunction, IL-12/23p40, psoriasis
- MeSH terms
- Interleukin-22, Dermatitis, Atopic, Humans, Interleukins, Skin, Keratinocytes, Interleukin-4, Cytokines, Interleukin-13, Interleukin-17, Antimicrobial Cationic Peptides, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.